A utoimmune hepatitis (AIH) is an immunemediated liver disorder characterized by the presence of circulating autoantibodies and hypergammaglobulinemia with liver histology showing interface hepatitis. 1 AIH can progress to cirrhosis, liver failure, and death if untreated. 2 Corticosteroids, alone or in combination with azathioprine (AZA), remain the standard initial treatment of AIH. This therapy is effective in controlling inflammatory activity, reversing or preventing fibrosis progression, and prolonging survival in the majority of patients. 1, 2 However, up to 20% of patients do not respond, or are intolerant to standard treatment. There are reports of alternative immunosuppressive drug therapies including cyclosporine, methotrexate, 6-mercaptopurine, rituximab, everolimus, mycophenolate mofetil (MMF), tacrolimus, and infliximab, but there is no established rescue therapy in AIH. [3] [4] [5] Different studies using MMF and tacrolimus as initial or rescue therapy have reported variable success rates. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Although some studies have reported that MMF is effective in nonresponders and in patients who are intolerant to standard therapy, other studies have suggested that MMF is an alternative only for AZAintolerant patients. [6] [7] [8] [9] [10] [11] Tacrolimus also has been used successfully in AIH patients who failed to respond to standard treatment. [12] [13] [14] [15] [16] The evidence regarding the efficacy and safety of these agents, however, is based on case series of limited size with short follow-up periods. These limitations preclude formally recommending MMF and/or tacrolimus for patients failing standard therapy. AIH is a rare disease and few patients are considered for second-line therapy. To overcome these limitations and to add to our current knowledge, we conducted a large international multicenter study to evaluate retrospectively the efficacy and safety of MMF and tacrolimus in AIH patients who were nonresponsive or intolerant to standard immunosuppressive therapy.
Patients and Methods

Study Design
We collected data from patients with an established AIH diagnosis from 19 centers across Europe, the United States, Canada, and China. AIH was diagnosed based on a combination of autoimmune serology, serum g globulin or IgG levels, and compatible liver biopsy findings. 17 Overlaps of AIH with primary biliary cholangitis and primary sclerosing cholangitis were classified according to suggested international guidelines. 18 All patients who were treated with second-line agents were identified. Patients with insufficient information or noncompliance with therapy, patients presenting with acute severe AIH, as well as patients diagnosed with overlapping primary biliary cholangitis or primary sclerosing cholangitis were excluded. A flow chart for patient inclusion is presented in Figure 1 .
Baseline and Follow-Up Data
Collected patient data included sex, age, and laboratory parameters according to Table 1 . We recorded data on standard therapy (initial doses, therapy duration, and response to treatment) and reasons for switching to second-line therapy. Local pathologists in the participating centers evaluated liver biopsy specimens; data from their reports were used in the study. Fibrosis was classified according to the METAVIR scoring system. 19 
Stratification Based on Reason for Second-Line Therapy
Patients were divided into 2 groups depending on the reason for switching therapy to second-line therapy. Group 1 patients had a complete response to standard therapy, but were switched to second-line therapy because of side effects to steroids or AZA. Group 2 patients had no response to standard therapy.
In this study, a complete biochemical response was defined as normalization of serum aminotransferase and IgG levels at any time within 6 months after starting therapy. Anything less than a complete response was considered a nonresponse. 1 
Statistical Analysis
Visual (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk tests) were used to determine the normality of continuous variables. Noncontinuous variables were expressed as medians (minimum-maximum). The chi-squared test, where appropriate, was used to compare the frequencies in different groups. The Wilcoxon signed-rank test was used for comparison of initial and final doses of MMF, tacrolimus, and corticosteroid therapy. The Kaplan-Meier method was used to calculate mortality, from the time of second-line therapy to liver-related death and/or need for liver transplantation, using the log-rank test. SPSS software version 22 (SPSS, Chicago, IL) and MedCalc version 14 (MedCalc, Ghent, Belgium) were used to perform statistical analysis, and a P value less than .05 was considered statistically significant.
Results
Characteristics of the Patient Population
The medical records of 2260 patients with AIH were evaluated. Among 302 identified AIH patients treated with second-line agents, 171 received MMF, 114 received tacrolimus, 12 received cyclosporine, 2 received everolimus, and 1 patient each received cyclophosphamide, rituximab, or methotrexate. The final study group included 201 AIH patients, 121 received MMF and 80 received tacrolimus (Figure 1 ). The number of cases from each participating center is presented in Supplementary Table 1 .
All patients initially received standard-of-care (SOC) therapy (20- according to biochemical and clinical response. A combination of MMF and tacrolimus or a switch between these agents was considered for patients with a suboptimal response or drug side effects. The reasons for switching from SOC therapy to secondline therapy are presented in Table 2 . In the stratification based on response to SOC therapy, 108 (53.7%) patients were stratified to group 1 (intolerant to SOC), and 93 (46.3%) to group 2 (nonresponders to SOC). Among patients treated with MMF, 74 (61.2%) patients were in group 1 and 47 (38.8%) patients were in group 2. In patients treated with tacrolimus, 34 (42.5%) patients were in group 1 and 46 (57.5%) patients were in group 2 ( Table 3 ).
Response to Second-Line Therapy
The efficacy of MMF and tacrolimus in patients with AIH is presented in Table 3 . Overall, the complete response rates were similar between MMF-and tacrolimus-treated patients (69.4% vs 72.5%, respectively; P ¼ .639). MMF and tacrolimus maintained biochemical response in 91.9% and 94.1%, respectively, of patients in group 1 (P ¼ .682). Significantly more group 2 patients given tacrolimus compared with MMF had a complete response (56.5% vs 34%, respectively; P ¼ .029). The rates of complete response were significantly lower in group 2 than in group 1, both for patients treated with MMF and for patients treated with tacrolimus (P < .001) (Figure 2) .
In responders to second-line therapy, the median initial and follow-up doses for MMF were 1500 (range, 500-2000) and 1000 (range, 0-2000) mg/d, and for tacrolimus were 4 (range, 1-8) and 3 (range, 0-6) mg/d, respectively (P < .001 for both). After initiation of MMF, the median steroid dose was decreased from 10 (range, 2.5-22.5) to 5 (range, 0-10) mg/d, and after initiation of tacrolimus from 10 (range, 5-50) to 5 (range, 0-10) mg/d (P < .001 for both). During maintenance therapy, the steroid therapy was withdrawn completely in 26 patients treated with MMF and in 20 patients treated with tacrolimus.
Management of Suboptimal Response
Seven nonresponders to MMF showed a complete response after switching to tacrolimus. A combination of MMF and tacrolimus was used in 8 suboptimal responders to either agent. This resulted in a complete response in 6 patients.
Second-Line Withdrawal and Side Effects
Withdrawal of second-line therapy was attempted in 14 patients after long-term remission. Six patients (4 receiving MMF, 2 receiving tacrolimus) maintained biochemical remission during follow-up evaluation, however, 8 relapsed and were re-treated successfully with the previous regimen.
Side effects that required drug discontinuation were seen in 8.3% (10 of 121) of MMF-treated patients and in 12.5% (10 of 80) of tacrolimus-treated patients (P ¼ .326). MMF was stopped because of leukopenia (n ¼ 6), gastrointestinal side effects (n ¼ 3), and headache (n ¼ 1). MMF was switched to standard therapy (n ¼ 4) or to tacrolimus (n ¼ 5), and 1 patient declined further therapy. Moreover, MMF had to be discontinued because of pregnancy in 2 patients and because of lymphoproliferative disorder in 1 patient. Tacrolimus was stopped because of neurologic side effects (n ¼ 4), hypertension and generalized edema (n ¼ 2), gastrointestinal side effects (n ¼ 2), hair loss (n ¼ 1), and renal failure (n ¼ 1). Tacrolimus was converted to standard therapy (n ¼ 5), to MMF (n ¼ 4), or to everolimus (n ¼ 1). Figure 2. Therapy response rates for patients treated with MMF and tacrolimus. Complete response rates were decreased significantly through group 1 to group 2 (P < .001 for both). 
Follow-Up Duration and Outcome
The median follow-up time of 62 months (range, 6-190 mo) was similar for patients treated with MMF and tacrolimus, 45 (range, 6-169) vs 73 (range, 7-190) months, respectively (P ¼ .140). The 5-and 10-year follow-up rates were 46.5% (53 of 114) and 22.8% (26 of 114) for MMF, and 59.7% (52 of 87) and 16.1% (14 of 87) for tacrolimus, respectively.
Liver biopsy was performed in 32 patients before second-line therapy was initiated and in 24 of these patients was repeated after a median of 38 months (range, 24-78 mo) of biochemical remission. Fibrosis progression was observed in 20% (2 of 10) and 21.4% (3 of 14) of patients treated with MMF and tacrolimus, respectively (P ¼ .932). Eight of 32 patients had stage IV fibrosis before second-line therapy. In 4 of these 8 patients, fibrosis remained stable or decreased whereas 4 patients progressed to liver failure. Five patients died from non-liver-related causes, 8 patients died from liverrelated causes, and 16 patients underwent liver transplantation during the follow-up period. At the time of writing this article, 10 patients (8 receiving MMF, 2 receiving tacrolimus) were on a liver transplant waiting list. The rates of liver-related death or transplantation were similar in the MMF (13.2%, n ¼ 15) and tacrolimus (10.3%, n ¼ 9) groups (log rank P ¼ .472) (Figure 3) .
Discussion
For the significant number of AIH patients who do not tolerate or have a suboptimal response to SOC therapy, the future holds a risk for cirrhosis, liver failure, liver transplantation, or death. [20] [21] [22] Additional treatment options beyond standard therapy with steroids and azathioprine therefore are needed. Over the years, several second-line options have been evaluated, but reports have been limited to small case series. This study represents a large cohort of patients exposed to alternative immunosuppression for the management of AIH. Derived from many treatment centers across Europe, China, and North America, it represents a real-world experience of both MMF and tacrolimus in patients with AIH.
In earlier studies, 6, 7, 23 MMF induced or maintained biochemical remission in 43% to 88% of AZA-intolerant patients. Unlike these studies, we did not consider progression to liver failure or stopping MMF owing to side effects to be the definition of treatment failure if the patient continued to be in biochemical remission. This difference in definition criteria may contribute to the higher success rate of MMF in our study group.
Existing data regarding the efficacy of MMF in nonresponders to SOC therapy are inconclusive. Some reports found MMF to be effective, whereas other studies reported complete response rates less than 25% in nonresponders to SOC therapy. [6] [7] [8] [9] [10] Our study results, with a 34% success rate of MMF in nonresponders to SOC therapy, are consistent with the latter reports.
Multiple small observational reports have evaluated tacrolimus as second-line therapy in AIH. In 3 studies, tacrolimus promoted or maintained remission in 93% (31 of 33) of treated patients. [13] [14] [15] In another study, tacrolimus induced biochemical remission in 77% (7 of 9) of acute AIH. 24 More recently, Than et al 25 reported that 52% (9 of 17) of AIH patients responded to tacrolimus. We found a 56.5% (26 of 46) complete response rate to tacrolimus in patients failing SOC therapy. Collectively, our results and earlier results suggest that tacrolimus may be superior to MMF as an alternative therapy in patients with nonresponse to standard therapy.
In our study, 7 patients entered remission after switching from MMF to tacrolimus. A combination of MMF and tacrolimus induced a biochemical response in 6 patients after an insufficient response to single therapy with either agent alone. Recently, Weiler et al 4 reported successful rescue treatment with infliximab in 11 AIH patients, of whom a majority failed to respond to MMF and/or tacrolimus. These results suggest that a significant proportion of AIH patients still need alternative treatment strategies. Molecular interventions that block multiple and different pathways or that strengthen immune tolerance may provide paths forward in the treatment of AIH. There is a risk for an increased frequency of drug-induced complications with combination therapy. Balancing the potential treatment-related side effects from overimmunosuppression may prove to be a challenge.
We particularly focused on severe drug-related side effects of MMF or tacrolimus that resulted in therapy withdrawal. Therefore, information about minor side effects that were tolerated or resolved with dose adjustments were not collected and analyzed in detail. The participating centers reported no cases of skin malignancies and only 1 case with lymphoproliferative disorder during MMF therapy. However, the case data forms did not specifically ask for information on malignancies. In 2 patients MMF was discontinued during pregnancy. The teratogenic potential of MMF should be explained carefully to all patients of childbearing age. The retrospective nature of our study may overestimate the safety profile of MMF or tacrolimus. Considering the long follow-up period and the available collected data, we can conclude that both agents appear to be safe alternatives for long-term use in AIH.
A complete biochemical response, the prevention of fibrosis progression, and the permanent withdrawal of immunosuppression are desirable objectives in AIH. 2, 20 Of note, 21% of patients who were treated with MMF/ tacrolimus had fibrosis progression in follow-up biopsies despite maintaining long-term complete biochemical response. This finding is in line with a recent large study on AIH. 21 Successful long-term withdrawal of MMF or tacrolimus was achieved in 6 of our patients. Because few alternative therapies are available if MMF and/or tacrolimus fail to control disease activity, we cannot recommend routinely attempting discontinuation of second-line agents.
Overall, the frequency of liver-related death/transplantation was not different, despite a higher biochemical response rate in the tacrolimus groups. This may be owing to some of the MMF nonresponders progressing to liver failure with the complication being managed successfully by switching to or combining therapy with tacrolimus.
Second-line agents are more expensive than standard immunosuppression and cost effectiveness may be an important issue in patients treated with MMF or tacrolimus. 22 Predniso(lo)ne, at daily doses exceeding 10 mg for more than 2 years, is associated with several side effects including osteoporosis, bone fractures, diabetes, hypertension, obesity, and psychiatric suffering.
1 Suboptimal AIH therapy also is expensive. Progression to liver failure resulting in experimental medication, morbidity, liver transplantation, and other health care efforts comes at a price. In our study, MMF and tacrolimus were tapered to minimal effective doses per biochemical response. Steroid therapy also was possible to reduce to low doses and that undoubtedly minimized its side effects. AIH is a life-long condition for most patients. Beyond the market price of drugs, all of these factors have to be balanced into the equation when cost effectiveness is discussed.
Our study had all the limitations of a retrospective study. Potentially relevant baseline genetic, serologic, and histologic features that might affect the therapeutic response were not fully available for all patients. This limitation precluded identifying independent predictors of the response to therapy with MMF and tacrolimus. Indications, drug doses, and types of second-line therapy were decided on in a nonstandardized way. The initial doses of standard therapy and steroid-tapering protocols were not identical among physicians. Also, some patients were treated initially by the referring center. All of these factors may have lead to a bias in our results. However, only expert centers participated in the study and we are confident that the management of these patients was of high standard according to international guidelines. Our study reflects real-life experiences and we hope that it will be helpful to clinicians in the selection of an appropriate second-line therapy.
In conclusion, the results of this retrospective and noncomparative study suggest that MMF and tacrolimus are safe alternative agents with durable immunosuppressive effects in the treatment of AIH in a significant proportion of patients. MMF and tacrolimus are equally capable of inducing or maintaining remission in responders to SOC medication, but tacrolimus performed better than MMF for patients who previously failed standard therapy. However, approximately one third of our patients showed a suboptimal response to secondline therapy and some progressed to liver failure. This emphasizes the need for additional novel alternative therapies.
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